Key Takeaways
- Margin story intact, quarter lumpy: Gross margin improved to 55.2% YoY from 49.2% on the mix shift to higher-margin products, though it dipped QoQ from 56.2% and EBITDA margin fell 330 bps on mix and lower operating leverage.
- CMS commercialization is the engine: Molecules that had been in development are now transitioning to commercial supply, driving the improved margin profile and giving management confidence the trajectory is sustainable, not a one-off.
- Balance sheet transformed: Free cash flow of ₹161 Crores in 9M FY23 cut net debt from ₹212 Crores to ₹72 Crores, even while investing ₹50.9 Crores in capex.
- Unit 3 nearing profitability: The new facility is ramping up, listed in the FDA database, and expected to turn profitable by the upcoming quarter, with utilization seen moving toward 68-69% in FY24.
- What to watch next quarter: Whether Unit 3 actually turns profitable, the pace of further CMS molecule commercialization, and whether gross margins hold at the current baseline absent raw-material or forex shocks.
CMS Business: The Margin Driver
- Commercialization inflection: Molecules that spent years in the development pipeline have begun transitioning to commercial supply, and this shift is the primary reason EBITDA margins improved from 15% in 9M FY22 to 19.5% in 9M FY23.
- Revenue sustainability: The CMS commercial revenue run rate of roughly ₹75 Crores is described as sustainable, not a one-time event, because the underlying molecules are now in commercial production rather than a launch spike.
- Pipeline quality step-change: Management says the quality of the recent CMS pipeline is significantly better than earlier vintages on every important parameter: annual revenue per molecule, margin profile, likelihood of drug success, and therapeutic area.
- Lumpiness is structural: Specialty molecules are small-volume and make-to-order, so quarterly revenues will be lumpy by nature; management asks investors to judge the trend on an annual basis, not quarter-to-quarter.
- Commercialization risk remains real: Because these are new drugs, there is always a risk the drug may not get approved or may not succeed commercially, so management remains cautious even as the trajectory improves.
Saharsh Davuluri: "the only caveat I would add is because these are new drugs there is always a risk that the drug may not get approved or there is also a risk that the drug may not be successful. So therefore we are still very cautious"
Margin Composition & Variability
- Gross margin baseline: Current gross margins are a reasonable baseline to model from, absent a crazy surge in raw materials or a big forex fluctuation, though management declined to break out margins by the three verticals (prime, specialty, CMS).
- Product-level dispersion is wide: Within CMS or specialty, some products carry 80% gross margins while others sit at 30-35%, so quarterly performance is a function of which specific products shipped in that period.
- EBITDA margin drop this quarter: The 330 bps QoQ decline to 19.5% for 9M was driven by a slight change in business mix and lower revenues impacting operating leverage, not by any structural cost problem.
- Raw material stability emerging: Raw material price uncertainty is present but starting to see some stability; the challenge has softened compared to three or four quarters ago, and the supply chain has been derisked from China over the last decade, with China-sourced procurement now roughly 25%.
Saharsh Davuluri: "I think it is hard to give you more granularity on how the gross margins will figure out, but I think what we are seeing is a good blend right now and unless there is a crazy surge in raw materials or maybe big fluctuation in forex. These margins are a reasonable baseline for now to take..."
Unit 3 & Capacity
- Ramp-up underway: Unit 3 is making both NCEs and generics, with product being consumed or set to be consumed in the US market; the site is listed in the FDA database and virtual audits have occurred, though no physical inspection has happened yet.
- Profitability imminent: Management expects Unit 3 to turn the corner and become profitable by the upcoming quarter. Utilization is projected to move closer to 68-69% in FY24 as product mix changes.
- Capacity strategy: Capital expenditure is typically added on the back of CMS molecules, with capacity fungible between GDS and CMS; the company looks two years ahead to ensure capacities are in place, and capex is trending around ₹100 Crores per year for maintenance plus upgrades.
- R&D capacity under review: Current R&D capacity should suffice tactically for the upcoming financial year, but from a two-to-three-year perspective it may not be enough; a decision on expansion will be made based on evaluation over the next six months.
Saharsh Davuluri: "I think decisions to expand will be based on what we figure out in the next six months or so. But I think definitely as a growing company we will have to make sure that R&D resources do not limit our ability to scale up more and more projects."
Specialty & Prime Segments
- Specialty growth drivers: Pipeline molecules where customers are taking quantities for launch drove growth, with Apixaban, Paliperidone, Donepezil and Ezetimibe all contributing meaningfully.
- Specialty QoQ decline explained: Specialty molecules are small-volume in nature, so customer campaigns are not run on a regular basis but are make-to-order based on demand over a period; over an annual period, specialty business has grown significantly.
- Prime business steady: Products like Mirtazapine and other medium-sized molecules around 100 to 200 tons are contributing consistently to revenues.
- GDS growth detail withheld: When asked to break down the 24% growth in the GDS segment into price and volume components, management declined, stating they would prefer to keep growth numbers to what was already shared.
Balance Sheet & Capital Allocation
- Debt reduction: Net debt fell to ₹72 Crores from ₹212 Crores at the end of March 2022, reflecting the resilience of the underlying business and free cash flow generation of ₹161 Crores in 9M FY23.
- Working capital stable: Management noted they are not facing the challenges others may be facing on receivables, and working capital remains as-is while gearing up for Q4.
- ROCE target: Management offered a broad range of 17 to 20% as a sustainable ROCE, without tying it to a specific current performance figure.
- Large growth capex deferred: Any large capital investments for growth will be communicated as and when they happen with board approval; the current ₹100 Crores annual run-rate covers maintenance and upgrades.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unit 3 profitability | Unit 3 expected to turn profitable | Upcoming quarter (Q4 FY23) |
| Unit 3 utilization | Move closer to 68-69% utilization | FY24 |
| CMS molecule commercialization | Expect maybe a couple more CMS molecules to commercialize; cumulatively should be good | Next one to two years |
| CMS business growth | Good healthy growth and profitability from CMS business | Next three to five years |
| Capex run-rate | Trending around ₹100 Crores per year for maintenance plus upgrades | Ongoing |
| R&D expansion decision | Decision on whether to expand R&D capacity | Next six months |
| Gross margin baseline | Current gross margins are a reasonable baseline, absent raw-material surge or big forex fluctuation | Ongoing, with stated caveats |
| ROCE range | Sustain in the broad range of 17 to 20% | Ongoing |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Gross margin | 55.2%, compared to 49.2% in Q3 FY22 and 56.2% in Q2 FY23 |
| Profit after tax | ₹30.4 cr, compared to ₹12.7 cr in Q3 FY22 |
| EPS | ₹23.7 per share |
| 9M FY23 total income | ₹785.8 cr, an increase of 12.3% over 9M FY22 |
| 9M FY23 EBITDA | ₹153.3 cr, an increase of 46.1% over 9M FY22 |
| 9M FY23 EBITDA margin | 19.5%, compared to 15% in 9M FY22 |
| 9M FY23 free cash flow | ₹161 cr |
| Net debt | ₹72 cr as of December 2022, reduced from ₹212 cr as of March 2022 |
| Net gearing ratio | 0.1x as of December 2022 |
| 9M FY23 capex | ₹50.9 cr |
| CMS business revenue share | 35%–40% of total revenues |
| Unit 1 and Unit 2 capacity utilization | 80%–85%, depending on quarter and product mix |
| Unit 3 capacity utilization | ~65% based on installed capacity; FY23 estimate 62%–65%, FY24 forecast 68%–69% |
| CMS commercial launch revenue | ~₹75 cr this quarter, up from an average of ₹40–50 cr over the prior four quarters |
| Procurement from China | ~25% of procurement, though dependence on China is far less |
| ROCE target | 17%–20% broad range |
| R&D scientists | 360–370 currently operating |